onartuzumab
glembatumumab
Ab
antinucleosome
vobarilizumab
iratumumab
-mab
agonistic monoclonal antibody
monoantibody
teplizumab
sibrotuzumab
dorlixizumab
serospecific
soravtansine
carlumab
mapatumumab
bococizumab
naptumomab estafenatox
anticorrelate
antidesmoglein
dalotuzumab
lexatumumab
thrombophylactic
drozitumab
guselkumab
evolocumab
robatumumab
immunoglobin
ipilimumab
adecatumumab
milatuzumab
zanolimumab
antiserum
antipolyvalent
autocentromere
siltuximab
thrombosuppressive
antisubstance
dacetuzumab
elotuzumab
teprotumumab
tucotuzumab
figitumumab
pamrevlumab
sonepcizumab
antiphosphospecific
bavituximab
cergutuzumab
thrombocythemia
seroblock